Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.

Franceschi S.

Recent Results Cancer Res. 2005;166:277-97. Review.

PMID:
15648196
2.

Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.

Adams M, Jasani B, Fiander A.

Vaccine. 2007 Apr 20;25(16):3007-13. Epub 2007 Jan 18. Review.

PMID:
17292517
3.

Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking.

Castellsagué X, Muñoz N.

J Natl Cancer Inst Monogr. 2003;(31):20-8. Review.

PMID:
12807941
4.
5.

[Vaccination against human papillomavirus for the prevention of cervical cancer].

Quint WG, ter Harmsel WA, van Doorn LJ.

Ned Tijdschr Geneeskd. 2006 Jun 24;150(25):1380-4. Review. Dutch.

PMID:
16841585
6.

Integrating human papillomavirus vaccination in cervical cancer control programmes.

Franco EL, Coutlée F, Ferenczy A.

Public Health Genomics. 2009;12(5-6):352-61. doi: 10.1159/000214925. Epub 2009 Aug 11. Review.

PMID:
19684447
7.

Human papillomavirus, cervical cancer, and the vaccines.

Tovar JM, Bazaldua OV, Vargas L, Reile E.

Postgrad Med. 2008 Jul;120(2):79-84. doi: 10.3810/pgm.2008.07.1794. Review.

PMID:
18654072
9.

[Experimental vaccines for sexually transmitted infections].

Jovanović M, Karadaglić D, Golusin Z, Brkić S, Poljacki M.

Med Pregl. 2009 Jan-Feb;62(1-2):42-8. Review. Serbian.

PMID:
19514600
11.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

12.

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.

Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM.

Eur J Gynaecol Oncol. 2005;26(2):129-42. Review.

PMID:
15857016
13.
14.

The epidemiology of human papillomavirus infection and cervical cancer.

Bosch FX, de Sanjosé S.

Dis Markers. 2007;23(4):213-27. Review.

15.

Environmental co-factors in HPV carcinogenesis.

Castellsagué X, Bosch FX, Muñoz N.

Virus Res. 2002 Nov;89(2):191-9. Review.

PMID:
12445659
16.

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.

Lu B, Kumar A, Castellsagué X, Giuliano AR.

BMC Infect Dis. 2011 Jan 12;11:13. doi: 10.1186/1471-2334-11-13. Review.

17.

Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.

Broomall EM, Reynolds SM, Jacobson RM.

Postgrad Med. 2010 Mar;122(2):121-9. doi: 10.3810/pgm.2010.03.2129. Review.

PMID:
20203463
18.

Global burden of human papillomavirus and related diseases.

Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S.

Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. Review.

PMID:
23199955
19.

Efficacy and other milestones for human papillomavirus vaccine introduction.

Pagliusi SR, Teresa Aguado M.

Vaccine. 2004 Dec 16;23(5):569-78. Review.

PMID:
15630792
20.

Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.

Monsonego J, Cortes J, Greppe C, Hampl M, Joura E, Singer A.

Vaccine. 2010 Nov 29;28(51):8065-72. doi: 10.1016/j.vaccine.2010.10.017. Epub 2010 Nov 16. Review.

PMID:
20971114

Supplemental Content

Support Center